Innovative Medicines Initiative (IMI) Information Month

The Bulgarian Association for Personalized Medicine (BAPEMED), supported by
the Ministry of Education and Science, Bulgaria
and the Innovative Medicines Initiative (IMI)

organizes

ABOUT IMI

Innovative Medicines Initiative (IMI) is working to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI does this by facilitating collaboration between the key players involved in health research, including universities, research centres, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. IMI is the world’s biggest public-private partnership (PPP) in the life sciences. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI2 programme, the Initiative has a €3.3 billion budget for the period 2014-2020.

The goal of IMI, particularly in its second phase (IMI2, 2014-2020) is to develop next generation vaccines, medicines and treatments, such as new antibiotics. IMI2 projects will provide Europeans, including the increasing numbers of older people, with more efficient and effective medicines and treatments. Greater coordination across industry sectors will result in more reliable and faster clinical trials, and better regulation. IMI research and innovation efforts will also open new commercial possibilities based on new services and products. The research, industry and societal sectors involved in IMI2 will benefit from the cooperation and knowledge sharing which take place in these projects.

Website

IMI Information Month

IMI Information Month is an initiative of Bulgarian Association for Personalized Medicine (BAPEMED), and it is supported by IMI and its state representative for Bulgaria – Prof. Dr. Victoria Sarafian, as well as by the Ministry of Education and Science, Republic of Bulgaria.

Along with the general information about IMI, details for the upcoming funding opportunities in 2020 with focus on IMI2 – Calls 22 & 23 will be presented in the scope of the information campaign.

The aim is to boost application and participation of CE and SEE countries, Bulgaria in particular, in different IMI calls and projects.

For more details and up-to-date information, please visit www.imi.europa.eu

If you have any questions, please email us at office@bapemed.org